Becker's Healthcare January 26, 2026
The de novo ASC market is being reshaped by population shifts, site-of-service changes and the growing push toward value-based care, according to Leawood, Kan.-based NueHealth founder and chairman Dan Tasset.
As many existing ASCs struggle to adapt to new cost and care delivery models, de novo development is increasingly driven by the need for redesigned facilities rather than simple capacity expansion.
Editor’s note: This interview was edited lightly for clarity and length.
Question: How would you characterize the de novo ASC market right now, and is there anything misunderstood or underestimated about de novo ASC development right now?
Dan Tasset: There are a number of angles.
Number one, we’re seeing internal migration in this country from certain states...
Today's Sponsors
Today's Sponsor